Evaluating the efficacy of the praziquantel dose pole for schistosomiasis treatment: A multi-country systematic review.

ABSTRACT: Schistosomiasis is a neglected tropical disease targeted for elimination as a public health problem by 2030 under the WHO's roadmap. Praziquantel, administered via the dose pole, which estimates the number of tablets needed for treatment according to an individual's height, has been used as preventive chemotherapy (PC) for 25 years, particularly for school-aged children (SAC). In 2022, PC was required for schistosomiasis in 50 countries, affecting a total of 264.3 million people, including 129.4 million adults. This systematic review evaluates the accuracy of the praziquantel dose pole across 64,212 individuals from 21 countries, focusing on its efficacy in delivering optimal, acceptable, insufficient, and excessive doses during school-based and community-wide treatment campaigns for schis

SUBMITTER: Berry P 

PROVIDER: S-EPMC12513654 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature